Radioiodinated 3-Fluoropropyl-nor-beta-CIT Synthesis via Arylsilane
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing I-123 radioiodinated 3-fluoropropyl-nor-β-CIT require the use of toxic hexamethylditin and ozone-depleting 3-fluoro-1-bromopropane, necessitating safer alternatives for production.
Innovation Solution
A process using an arylsilane intermediate and 3-fluoropropanal for the preparation of I-123 radioiodinated 3-fluoropropyl-nor-β-CIT, which avoids hexamethylditin and 3-fluoro-1-bromopropane, involving steps such as Grignard addition, demethylation, and radioiododesilation reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If hexamethylditin is used for the conversion of arylstannane precursor to I-123 labeled compound, then the conversion is achieved, but the process becomes highly toxic and requires engineering controls and substantial personal protective equipment
Solution Approach 1:
The patent removes the toxic hexamethylditin reagent from the synthesis pathway entirely, replacing it with a non-toxic alternative method that achieves the same conversion of arylstannane precursor to I-123 labeled compound without requiring engineering controls or substantial personal protective equipment
Solution Approach 2:
The patent introduces an intermediary approach by using a different chemical pathway that avoids direct use of toxic tin reagents, thereby mediating the conversion process through safer chemical transformations that still achieve the desired radioiodination
2Ease of manufacture
If 3-fluoro-1-bromopropane is used for alkylation of nortropane to N-(3-fluoropropyl) analogue, then the alkylation is achieved, but the process becomes ozone depleting
Solution Approach 1:
The patent extracts and removes the ozone-depleting 3-fluoro-1-bromopropane reagent from the alkylation process, replacing it with an alternative alkylating agent that achieves the same N-(3-fluoropropyl) analogue formation without ozone depletion concerns
Solution Approach 2:
The patent changes the chemical parameters of the alkylating agent from an ozone-depleting bromopropane derivative to a non-ozone-depleting alternative, thereby modifying the reaction conditions to eliminate environmental harm while maintaining the alkylation functionality
3Productivity
If the conventional six step process is used for preparation of I-123 radioiodinated 3-fluoropropyl-nor-β-CIT, then the compound is produced, but the process requires toxic and hazardous materials
Solution Approach 1:
The patent removes multiple hazardous materials from the six-step synthesis process, including hexamethylditin and 3-fluoro-1-bromopropane, by replacing them with non-toxic alternatives that maintain production efficiency while eliminating the need for special safety measures
Solution Approach 2:
The patent converts the harmful six-step process involving toxic reagents into a beneficial streamlined process by eliminating dangerous materials and reducing step count, thereby transforming a hazardous manufacturing route into a safe and efficient one
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process reduces the number of steps and eliminates the use of hazardous materials, providing a safer and more efficient method for producing I-123 radioiodinated 3-fluoropropyl-nor-β-CIT for diagnostic applications.
Implementation Method 1
contacting a nortropane compound (II) with 3-fluoropropanal to form compound (III)
Implementation Method 2
contacting a nortropane compound (II) with 3-fluoropropanal in the presence of a reducing agent, to form compound (III)
Implementation Method 3
The present invention relates to the preparation of I-123 radioiodinated 3-fluoropropyl-nor-β-CIT using an arylsilane intermediate
Data Source
AI summary
The invention generally provides processes for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT. In particular, the process uses an arylsilane intermediate, thus avoiding the use of hexamethylditin, and reducing the number of steps previously required for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT from anhydroecgonine methyl ester. The invention also relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analogue using 3-fluoropropanal.